TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Solifenacin in the Treatment of Urgency Symptoms of Overactive Bladder in a Rising Dose, Randomized, Placebo-controlled, Double-blind Trial
Brief Summary: Prospective, double-blind, double-randomised, 2-arm parallel group study. Optimal dose increase. Primary efficacy assessment of OAB symptoms by patient diaries.


Options:
A: Arm Label: Behavioral Training; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral training | Arm Label: Drug Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxybutynin chloride, extended-release | Intervention Type: BEHAVIORAL; Name: Behavioral training; Assigned to Arm(s): Behavioral Training | Intervention Type: DRUG; Name: Oxybutynin chloride, extended-release; Assigned to Arm(s): Drug Therapy
B: Arm Label: I.Solifenacin succinate 10mg (2x5mg 1/day); Type: EXPERIMENTAL; Interventions: Drug: Solifenacin Succinate | Arm Label: II.Solifenacin succinate 5mg (5mg 1/day); Type: EXPERIMENTAL; Interventions: Drug: Solifenacin Succinate | Arm Label: III.Oxybutynin hydrochloride 15mg (5mg 3/day); Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxybutynin Hydrochloride | Arm Label: IV. Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Solifenacin Succinate; Assigned to Arm(s): I.Solifenacin succinate 10mg (2x5mg 1/day) | Intervention Type: DRUG; Name: Solifenacin Succinate; Assigned to Arm(s): II.Solifenacin succinate 5mg (5mg 1/day) | Intervention Type: DRUG; Name: Oxybutynin Hydrochloride; Assigned to Arm(s): III.Oxybutynin hydrochloride 15mg (5mg 3/day) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): IV. Placebo
C: Arm Label: I; Type: EXPERIMENTAL; Interventions: Drug: Solifenacin succinate | Arm Label: II; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Solifenacin succinate; Assigned to Arm(s): I | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): II
D: Arm Label: Gabapentin; Type: EXPERIMENTAL; Interventions: Drug: Gabapentin | Arm Label: Solifenacin Succinate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Solifenacin Succinate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo drugs | Intervention Type: DRUG; Name: Gabapentin; Assigned to Arm(s): Gabapentin | Intervention Type: DRUG; Name: Solifenacin Succinate; Assigned to Arm(s): Solifenacin Succinate | Intervention Type: DRUG; Name: Placebo drugs; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Immunogenicity and Safety Study of Different Formulations of GSK Biologicals' Herpes Zoster Vaccine 1437173A When Administered Twice in Adults Aged 50 Years and Older
Brief Summary: The goal of this randomized observer-blind trial is to further refine the formulation of vaccines containing GSK1437173A in older adults by comparing the cellular and humoral immune responses and the safety profiles of the different formulations.


Options:
A: Arm Label: SC HZ/su Group; Type: EXPERIMENTAL; Interventions: Biological: Herpes zoster vaccine GSK1437173A | Arm Label: IM HZ/su Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Herpes zoster vaccine GSK1437173A | Intervention Type: BIOLOGICAL; Name: Herpes zoster vaccine GSK1437173A; Assigned to Arm(s): IM HZ/su Group, SC HZ/su Group
B: Arm Label: GSK1437173A formulation 1 Group; Type: EXPERIMENTAL; Interventions: Biological: Herpes zoster vaccine GSK1437173A | Arm Label: GSK1437173A formulation 2 Group; Type: EXPERIMENTAL; Interventions: Biological: Herpes zoster vaccine GSK1437173A | Arm Label: GSK1437173A formulation 3 Group; Type: EXPERIMENTAL; Interventions: Biological: Herpes zoster vaccine GSK1437173A | Arm Label: Control Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Herpes zoster vaccine GSK1437173A; Assigned to Arm(s): GSK1437173A formulation 1 Group, GSK1437173A formulation 2 Group, GSK1437173A formulation 3 Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Control Group
C: Arm Label: Co-Ad Group; Type: EXPERIMENTAL; Interventions: Biological: Herpes Zoster vaccine GSK 1437173A, Biological: Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23™ | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Herpes Zoster vaccine GSK 1437173A, Biological: Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23™ | Intervention Type: BIOLOGICAL; Name: Herpes Zoster vaccine GSK 1437173A; Assigned to Arm(s): Co-Ad Group, Control Group | Intervention Type: BIOLOGICAL; Name: Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23™; Assigned to Arm(s): Co-Ad Group, Control Group
D: Arm Label: Concomitant Vaccination; Type: EXPERIMENTAL; Interventions: Biological: ZOSTAVAX™, Biological: Placebo to ZOSTAVAX™, Biological: Influenza Vaccine | Arm Label: Nonconcomitant Vaccination; Type: EXPERIMENTAL; Interventions: Biological: ZOSTAVAX™, Biological: Placebo to ZOSTAVAX™, Biological: Influenza Vaccine | Intervention Type: BIOLOGICAL; Name: ZOSTAVAX™; Assigned to Arm(s): Concomitant Vaccination, Nonconcomitant Vaccination | Intervention Type: BIOLOGICAL; Name: Placebo to ZOSTAVAX™; Assigned to Arm(s): Concomitant Vaccination, Nonconcomitant Vaccination | Intervention Type: BIOLOGICAL; Name: Influenza Vaccine; Assigned to Arm(s): Concomitant Vaccination, Nonconcomitant Vaccination

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Immunogenicity and Safety Study of Different Formulations of GSK Biologicals' Herpes Zoster Vaccine 1437173A When Administered Twice in Adults Aged 50 Years and Older
Brief Summary: The goal of this randomized observer-blind trial is to further refine the formulation of vaccines containing GSK1437173A in older adults by comparing the cellular and humoral immune responses and the safety profiles of the different formulations.


Options:
A: Arm Label: GSK1437173A group; Type: EXPERIMENTAL; Interventions: Biological: Herpes Zoster Vaccine GSK1437173A | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Herpes Zoster Vaccine GSK1437173A; Assigned to Arm(s): GSK1437173A group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo group
B: Arm Label: GSK1437173A formulation 1 Group; Type: EXPERIMENTAL; Interventions: Biological: Herpes zoster vaccine GSK1437173A | Arm Label: GSK1437173A formulation 2 Group; Type: EXPERIMENTAL; Interventions: Biological: Herpes zoster vaccine GSK1437173A | Arm Label: GSK1437173A formulation 3 Group; Type: EXPERIMENTAL; Interventions: Biological: Herpes zoster vaccine GSK1437173A | Arm Label: Control Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Herpes zoster vaccine GSK1437173A; Assigned to Arm(s): GSK1437173A formulation 1 Group, GSK1437173A formulation 2 Group, GSK1437173A formulation 3 Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Control Group
C: Arm Label: Single Dose of Zostavax; Type: EXPERIMENTAL; Interventions: Biological: Zostavax | Arm Label: Zostavax - Day 0 and Month 1; Type: EXPERIMENTAL; Interventions: Biological: Zostavax | Arm Label: Zostavax - Day 0 and Month 3; Type: EXPERIMENTAL; Interventions: Biological: Zostavax | Intervention Type: BIOLOGICAL; Name: Zostavax; Assigned to Arm(s): Single Dose of Zostavax, Zostavax - Day 0 and Month 1, Zostavax - Day 0 and Month 3
D: Arm Label: GSK1437173A 18-30 Years Old Group; Type: EXPERIMENTAL; Interventions: Procedure: Blood sampling for assay of persistence of immunogenicity | Arm Label: GSK1437173A 50-70 Years Old Group; Type: EXPERIMENTAL; Interventions: Procedure: Blood sampling for assay of persistence of immunogenicity | Intervention Type: PROCEDURE; Name: Blood sampling for assay of persistence of immunogenicity; Assigned to Arm(s): GSK1437173A 18-30 Years Old Group, GSK1437173A 50-70 Years Old Group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Single-arm, International, Multi-center Trial Investigating the Efficacy and Safety of Ofatumumab Retreatment and Maintenance in CLL Patients Who Progressed Following Response or Stable Disease After Ofatumumab Treatment in Hx-CD20-406
Brief Summary: The purpose of the trial is to investigate the efficacy and safety of ofatumumab retreatment and maintenance in patients with chronic lymphocytic leukemia who have previously responded or had disease stabilization after ofatumumab in an ongoing trial (Hx-CD20-406).


Options:
A: Arm Label: PCI-32765; Type: EXPERIMENTAL; Interventions: Drug: PCI-32765 | Intervention Type: DRUG; Name: PCI-32765; Assigned to Arm(s): PCI-32765
B: Arm Label: Rituximab + PCI-32765; Type: EXPERIMENTAL; Interventions: Drug: Rituximab, Drug: PCI-32765 | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Rituximab + PCI-32765 | Intervention Type: DRUG; Name: PCI-32765; Assigned to Arm(s): Rituximab + PCI-32765
C: Arm Label: Ofatumumab; Type: EXPERIMENTAL; Interventions: Drug: Ofatumumab | Intervention Type: DRUG; Name: Ofatumumab; Assigned to Arm(s): Ofatumumab
D: Arm Label: Ofatumumab; Type: EXPERIMENTAL; Interventions: Drug: Ofatumumab | Arm Label: Physicians' Choice; Type: ACTIVE_COMPARATOR; Interventions: Drug: Physicians' Choice | Intervention Type: DRUG; Name: Ofatumumab; Assigned to Arm(s): Ofatumumab | Intervention Type: DRUG; Name: Physicians' Choice; Assigned to Arm(s): Physicians' Choice

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective Study on the Efficacy of 1.5mg Bevacizumab Versus Selective Subthreshold Micropulslaser in Central Serous Chorioretinopathy
Brief Summary: The purpose of this study is to evaluate the clinical efficacy of an initial subthreshold retinal micropulselasercoagulation versus a single intravitreal 1.5mg bevacizumab injection in central serous choriretinopathy, as the micropulse will selectively treat the damaged RPE to induce reproliferation of healthy RPE cells, whereas the intravitreal injection should non-selectively stop the RPE leakage.


Options:
A: Arm Label: Low-fluence PDT with Verteporfin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Verteporfin | Arm Label: Ranibizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: ranibizumab | Intervention Type: DRUG; Name: Verteporfin; Assigned to Arm(s): Low-fluence PDT with Verteporfin | Intervention Type: DRUG; Name: ranibizumab; Assigned to Arm(s): Ranibizumab
B: Arm Label: Selective Retinatherapy (SRT); Type: EXPERIMENTAL; Interventions: Device: Selective Retina Therapy (SRT) | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: crossover; Type: EXPERIMENTAL; Interventions: Device: Selective Retina Therapy (SRT) | Intervention Type: DEVICE; Name: Selective Retina Therapy (SRT); Assigned to Arm(s): Selective Retinatherapy (SRT), crossover
C: Arm Label: Half-dose photodynamic therapy (PDT); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Half-dose photodynamic therapy (PDT) | Arm Label: Micropulse laser (ML) treatment; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Micropulse laser (ML) treatment | Intervention Type: PROCEDURE; Name: Half-dose photodynamic therapy (PDT); Assigned to Arm(s): Half-dose photodynamic therapy (PDT) | Intervention Type: PROCEDURE; Name: Micropulse laser (ML) treatment; Assigned to Arm(s): Micropulse laser (ML) treatment
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Device: subthreshold micropulselaser, Drug: bevacizumab | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: subthreshold micropulselaser | Arm Label: 3; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: subthreshold micropulselaser; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): 1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors, Independent Investigator Study
Brief Summary: This is a 8-week double-blind placebo controlled parallel group study of the efficacy of varenicline (Chantix) for smoking cessation in schizophrenic patients, and its effect on cognitive function in patients with schizophrenia.At some sits evaluation of smoking measures is extended to 12 weeks. Correlations will be made with biological predictors of efficacy: a) measures of nicotinic receptors in lymphocytes b) DNMT1 and GAD67 mRNA in lymphocytes. Subjects will be current cigarette smokers or history of regular smokers.


Options:
A: Arm Label: Intervention arm; Type: EXPERIMENTAL; Interventions: Behavioral: intensive multi-disciplinary education program on tobacco treatment for pharmacists | Arm Label: Control arm; Type: ACTIVE_COMPARATOR; Interventions: Other: Control arm | Intervention Type: BEHAVIORAL; Name: intensive multi-disciplinary education program on tobacco treatment for pharmacists; Assigned to Arm(s): Intervention arm | Intervention Type: OTHER; Name: Control arm; Assigned to Arm(s): Control arm
B: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Matched Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo for varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo for varenicline; Assigned to Arm(s): Matched Placebo
C: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline tartrate | Arm Label: bupropion; Type: ACTIVE_COMPARATOR; Interventions: Drug: bupropion hydrochloride | Arm Label: Nicotine Replacement Therapy Patch; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine Replacement Therapy Patch | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: varenicline tartrate; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: bupropion hydrochloride; Assigned to Arm(s): bupropion | Intervention Type: DRUG; Name: Nicotine Replacement Therapy Patch; Assigned to Arm(s): Nicotine Replacement Therapy Patch
D: Arm Label: P; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion HCl ER | Intervention Type: DRUG; Name: Bupropion HCl ER; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): P

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors, Independent Investigator Study
Brief Summary: This is a 8-week double-blind placebo controlled parallel group study of the efficacy of varenicline (Chantix) for smoking cessation in schizophrenic patients, and its effect on cognitive function in patients with schizophrenia.At some sits evaluation of smoking measures is extended to 12 weeks. Correlations will be made with biological predictors of efficacy: a) measures of nicotinic receptors in lymphocytes b) DNMT1 and GAD67 mRNA in lymphocytes. Subjects will be current cigarette smokers or history of regular smokers.


Options:
A: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Matched Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo for varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo for varenicline; Assigned to Arm(s): Matched Placebo
B: Arm Label: Ecig 24 mg nicotine; Type: EXPERIMENTAL; Interventions: Device: Ecig 24 mg nicotine | Arm Label: Ecig 0 mg nicotine; Type: SHAM_COMPARATOR; Interventions: Device: Ecig 0 mg nicotine | Arm Label: Nicotine free inhalator; Type: PLACEBO_COMPARATOR; Interventions: Device: Nicotine free inhalator | Intervention Type: DEVICE; Name: Ecig 24 mg nicotine; Assigned to Arm(s): Ecig 24 mg nicotine | Intervention Type: DEVICE; Name: Ecig 0 mg nicotine; Assigned to Arm(s): Ecig 0 mg nicotine | Intervention Type: DEVICE; Name: Nicotine free inhalator; Assigned to Arm(s): Nicotine free inhalator
C: Intervention Type: DRUG; Name: CP-526,555 (varenicline); Assigned to Arm(s): N/A
D: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors, Independent Investigator Study
Brief Summary: This is a 8-week double-blind placebo controlled parallel group study of the efficacy of varenicline (Chantix) for smoking cessation in schizophrenic patients, and its effect on cognitive function in patients with schizophrenia.At some sits evaluation of smoking measures is extended to 12 weeks. Correlations will be made with biological predictors of efficacy: a) measures of nicotinic receptors in lymphocytes b) DNMT1 and GAD67 mRNA in lymphocytes. Subjects will be current cigarette smokers or history of regular smokers.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: EVT 302 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: EVT 302 plus open label Nicotine replacement | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo plus open label Nicotine Replacement | Intervention Type: DRUG; Name: EVT 302; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: EVT 302 plus open label Nicotine replacement; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Placebo plus open label Nicotine Replacement; Assigned to Arm(s): 4
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Bupropion, Drug: nicotine transdermal patch | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: nicotine transdermal patch | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: nicotine transdermal patch; Assigned to Arm(s): 1, 2
C: Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Sugar Pil; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Sugar Pil
D: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Matched Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo for varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo for varenicline; Assigned to Arm(s): Matched Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors, Independent Investigator Study
Brief Summary: This is a 8-week double-blind placebo controlled parallel group study of the efficacy of varenicline (Chantix) for smoking cessation in schizophrenic patients, and its effect on cognitive function in patients with schizophrenia.At some sits evaluation of smoking measures is extended to 12 weeks. Correlations will be made with biological predictors of efficacy: a) measures of nicotinic receptors in lymphocytes b) DNMT1 and GAD67 mRNA in lymphocytes. Subjects will be current cigarette smokers or history of regular smokers.


Options:
A: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Transdermal Nicotine Patch; Type: EXPERIMENTAL; Interventions: Drug: Transdermal Nicotine Patch | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Transdermal Nicotine Patch; Assigned to Arm(s): Transdermal Nicotine Patch
B: Arm Label: Chantix (varenicline); Type: EXPERIMENTAL; Interventions: Drug: Chantix | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Chantix; Assigned to Arm(s): Chantix (varenicline) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Matched Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo for varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo for varenicline; Assigned to Arm(s): Matched Placebo
D: Arm Label: Standard Arm (Arm A); Type: ACTIVE_COMPARATOR; Interventions: Other: TOBACCO CIGARETTES | Arm Label: Intervention Arm (Arm B); Type: ACTIVE_COMPARATOR; Interventions: Other: COMBUSTION-FREE NICOTINE DELIVERY SYSTEMS (C-F NDS) | Intervention Type: OTHER; Name: TOBACCO CIGARETTES; Assigned to Arm(s): Standard Arm (Arm A) | Intervention Type: OTHER; Name: COMBUSTION-FREE NICOTINE DELIVERY SYSTEMS (C-F NDS); Assigned to Arm(s): Intervention Arm (Arm B)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors, Independent Investigator Study
Brief Summary: This is a 8-week double-blind placebo controlled parallel group study of the efficacy of varenicline (Chantix) for smoking cessation in schizophrenic patients, and its effect on cognitive function in patients with schizophrenia.At some sits evaluation of smoking measures is extended to 12 weeks. Correlations will be made with biological predictors of efficacy: a) measures of nicotinic receptors in lymphocytes b) DNMT1 and GAD67 mRNA in lymphocytes. Subjects will be current cigarette smokers or history of regular smokers.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Champix | Intervention Type: DRUG; Name: Champix; Assigned to Arm(s): Placebo
B: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Matched Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo for varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo for varenicline; Assigned to Arm(s): Matched Placebo
C: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline
D: Arm Label: placebo; Type: N/A; Interventions: Drug: placebo | Arm Label: varenicline; Type: N/A; Interventions: Drug: varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline

Answer: B